Radiopharm Theranostics Ltd (ASX:RAD) has strengthened its executive team as it continues to develop its deep pipeline of therapeutic radiopharmaceuticals.
The company is planning face-to-face meetings as part of its upcoming roadshow to update investors on its progress.
Roadshow
Radiopharm CEO and managing director Riccardo Canevari said: “I’m looking forward to my first face-to-face meetings with many of you in Australia as part of an upcoming roadshow for RAD.
“These past months have been difficult for all of us due to the constraints put upon international travel and as much as mediums such as Zoom allowed us to communicate, it is not the same as a direct handshake.”
He hopes to show shareholders “how we are transforming the company and working towards creating value for your investment with us.”
Shareholder debriefs will be held on March 28 in Sydney and on March 29 in Melbourne.
Those who wish to attend are advised to register their interest by March 24 by emailing alison@radiopharmtheranostics.com.
Management team
Canevari added: “We’ve bolstered our management team with exceptionally qualified leaders in the oncology field.”
In its December introductory newsletter, the company welcomed chief medical officer Professor David Mozley and chief technology officer Dr Thom Tulip.
Joining the company effective early this year are Dr Scot Harper as senior VP of Clinical Operations, Dr Gitasha Chand, global medical director, Dr Levente Meszaros, global director of Translational Science, Dr Antje Wegener, VP Clinical Development and Bill Regan as senior VP Regulatory Strategy.
“Their CVs reflect the very rarefied levels of professional achievement in the field of oncology,” Canevari said.
Its board has also been strengthened by the appointment of Hester Larkin as a non-executive director.
Canevari continued: “Her background in the pharmaceutical and medical imaging industries is a perfect fit for our business.
“Her leadership abilities are reflected in the driving of successful product launches of proprietary pharmaceuticals and imaging agents in oncology, cardiology, neurology and HIV.”
Unmet need
Canevari added: “There’s an apt phrase in our business … unmet need. That’s what’s driving us.
“We aim to become a recognised leader in this most worthy of tasks.
“Our ongoing research into and use of high and low energy isotopes for diagnostic as well as therapeutic uses in treating cancer is our goal and we look optimistically to the future as we strive to improve the outcomes of patients with oncological disease.
“We plan to start four new Phase 1 trials in 2022 and expect to have a Phase 2 readout by June 2022.”